Nutanix to help A/NZ businesses weather COVID-19 crisis


By Dylan Bushell-Embling
Thursday, 27 February, 2020

Nutanix to help A/NZ businesses weather COVID-19 crisis

Nutanix has announced an initiative to provide a free extended trial of its desktop-as-a-service solution Frame to businesses across Asia–Pacific including Australia and New Zealand, to help them cope with the impact of the economic impact of the novel coronavirus (COVID-19).

The 30-day trial will allow unlimited usage of the cloud-based desktop virtualisation software to allow for enhanced remote work capabilities for businesses impacted by restrictions on staff travel and congregation introduced to help manage the outbreak.

Nutanix Frame provides a virtual desktop without relying on or consuming any internal hardware. Virtual workspaces for individuals, teams, customers and partners can usually be up and running within an hour.

The solution provides secure remote access to a worker’s work desktop, files and network from anywhere on any device.

The agreement comes after Treasurer Josh Frydenberg declared that the economic impact from coronavirus will be worse than the bushfire crisis.

“We are trying to play our part in making sure Asia–Pacific’s businesses and economies keep moving during these unpredictable times,” said Nutanix Head of Asia Pacific and Japan Matt Young.

“The safety and security of staff remains the primary concern, but we can help keep them active, engaged and productive through easily available and accessible software.”

Image credit: ©stock.adobe.com/au/TRAVELARIUM

Related News

Zscaler launches Zero Trust Segmentation

Zscaler is taking a unique approach to protecting customers from the ransomware threat with its...

Akamai launches platform for building distributed apps

The new Akamai App Platform is designed to take some of the frustration and difficulty out of...

Nutanix expands collaboration with AWS

Nutanix will provide customers with the ability to run Nutanix Cloud Clusters on AWS as part of...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd